N-[(Z)-[(2S)-2-[(2S)-1-hydroxy-3-methoxy-4-oxobutan-2-yl]oxy-2-methoxyethylidene]amino]-3-sulfanylpropanamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[(Z)-[(2S)-2-[(2S)-1-hydroxy-3-methoxy-4-oxobutan-2-yl]oxy-2-methoxyethylidene]amino]-3-sulfanylpropanamide
• 化学式: C₁₁H₂₀N₂O₆S
• 分子量: 308.35
• InChiKey: REVYYUZAKUPMLY-JKXTWVHASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• TARGETED IDURONATE-2-SULFATASE COMPOUNDS
  申请人：Angiochem Inc.

  公开号：US20140335163A1

  公开（公告）日：2014-11-13

  The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.
• TARGETED LYSOSOMAL ENZYME COMPOUNDS
  申请人：Angiochem Inc.

  公开号：US20150037311A1

  公开（公告）日：2015-02-05

  The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.
• [EN] TARGETED IDURONATE-2-SULFATASE COMPOUNDS<br/>[FR] COMPOSÉS D'IDURONATE-2-SULFATASE CIBLÉS
  申请人：ANGIOCHEM INC

  公开号：WO2014082184A1

  公开（公告）日：2014-06-05

  The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, a compound that includes iduronate-2-sulfatase conjugated to Angiopep-2 through a linker formed by specific click chemistry reactions. In certain embodiments, these compounds, owing to the presence of the targeting moiety, can cross the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features pharmaceutical compositions containing such compounds and methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.